Under the collaboration, the two companies will work together on a phase two clinical trial to evaluate the efficacy of centanafadine extended-release capsules on adults with major depressive disorder, according to a Feb. 1 release from Verily.
The study, dubbed Juniper, will recruit 336 participants.
The move comes after Verily announced it would be sunsetting some of its healthcare projects and restructuring its leadership to focus on remote patient monitoring for heart failure and microneedles for drug delivery.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.